Overview

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Vortioxetine (Lu AA21004), once daily (QD), in Japanese participants with major depressive disorder. The purpose of this study is to assess the efficacy, safety and tolerability of 8-week treatment with Lu AA21004, once daily (QD), in Japanese participants with major depressive disorder.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Vortioxetine